Join Us at TIDES USA 2025 in San Diego! Mark your calendars! TIDES USA 2025—the premier event for oligonucleotide and peptide therapeutics—is coming to San Diego, USA, on May 19, 2025. Visit SINOPEG at Booth #613 to explore cutting-edge solutions in: Custom PEG Derivatives (mPEG, heterobifunctional PEGs, branched PEGs) Lipid Nanoparticles (LNPs) & Lipidoids for nucleic acid delivery Innovative Linker Technologies & ADC Payloads Why Stop By? Discuss your formulation challenges with our PEGylation experts Discover high-purity excipients for mRNA, siRNA, and peptide therapies Learn how our GMP-grade materials accelerate preclinical-to-commercial transitions Spotlight Case Study: Ask us about our role in developing temperature-stable LNP formulations for a global COVID-19 vaccine partner! Schedule a 1:1 Meeting: Avoid the crowds—reserve your private session today: sales@sinopeg.com Can't attend? Explore our solutions online: http://www.sinopeg.com Let's shape the future of oligonucleotide and peptide therapeutics together! See you at #613. #TIDES2025 DrugDiscovery #LNPs #mRNA #PeptideTherapeutics #BiotechInnovation

Exciting Announcement! SINOPEG is thrilled to announce that we will be exhibiting at TIDES USA 2025, taking place May 19–22 at the Manchester Grand Hyatt San Diego! Join us at Booth #613 to explore how SINOPEG continues to drive innovation in oligonucleotide and peptide therapeutics. As a trusted partner in the industry, we specialize in delivering high-quality building blocks, advanced intermediates, and customized solutions to accelerate your drug discovery and development projects. Why Visit Us? Discover our cutting-edge portfolio of products and services. Discuss collaboration opportunities with our expert team. Learn how we support global partners in overcoming complex R&D challenges. TIDES USA is the premier event for oligonucleotide and peptide therapeutics, and we're eager to connect with industry leaders, researchers, and innovators shaping the future of biopharma. Let's explore synergies and unlock new possibilities together! Save the Date: May 19–22, 2025 Location: Manchester Grand Hyatt San Diego Find Us: Booth #613 Can't wait to meet you there? Drop us a message or comment below – let's start the conversation today!

Mol Ther. 2022 Sep 7;30(9):3078-3094.   doi: 10.1016/j.ymthe.2022.07.007.   Epub 2022 Jul 12. mRNA-LNP vaccines tuned for systemic immunization induce strong antitumor immunity by engaging splenic immune cells Abstract mRNA vaccines have recently proved to be highly effective against SARS-CoV-2.   Key to their success is the lipid-based nanoparticle (LNP), which enables efficient mRNA expression and endows the vaccine with adjuvant properties that drive potent antibody responses.   Effective cancer vaccines require long-lived, qualitative CD8 T cell responses instead of antibody responses.   Systemic vaccination appears to be the most effective route, but necessitates adaptation of LNP composition to deliver mRNA to antigen-presenting cells.   Using a design-of-experiments methodology, we tailored mRNA-LNP compositions to achieve high-magnitude tumor-specific CD8 T cell responses within a single round of optimization.   Optimized LNP compositions resulted in enhanced mRNA uptake by multiple splenic immune cell populations.   Type I interferon and phagocytes were found to be essential for the T cell response.   Surprisingly, we also discovered a yet unidentified role of B cells in stimulating the vaccine-elicited CD8 T cell response.   Optimized LNPs displayed a similar, spleen-centered biodistribution profile in non-human primates and did not trigger histopathological changes in liver and spleen, warranting their further assessment in clinical studies.   Taken together, our study clarifies the relationship between nanoparticle composition and their T cell stimulatory capacity and provides novel insights into the underlying mechanisms of effective mRNA-LNP-based antitumor immunotherapy. Keywords: LNP;   cancer;   design-of-experiments methodology;   extrahepatic delivery;   immunotherapy;   mRNA;   vaccination. Excipient for DNA/RNA Delivery Lipid For more product information, please contact us at: US Tel: 1-844-782-5734 US Tel: 1-844-QUAL-PEG CHN Tel: 400-918-9898 Email: sales@sinopeg.com

Review J Nanobiotechnology. 2022 Jun 14;20(1):276. doi: 10.1186/s12951-022-01478-7. Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects Abstract In the last decade, the development of messenger RNA (mRNA) therapeutics by lipid nanoparticles (LNP) leads to facilitate clinical trial recruitment, which improves the efficacy of treatment modality to a large extent. Although mRNA-LNP vaccine platforms for the COVID-19 pandemic demonstrated high efficiency, safety and adverse effects challenges due to the uncontrolled immune responses and inappropriate pharmacological interventions could limit this tremendous efficacy. The current study reveals the interplay of immune responses with LNP compositions and characterization and clarifies the interaction of mRNA-LNP therapeutics with dendritic, macrophages, neutrophile cells, and complement. Then, pharmacological profiles for mRNA-LNP delivery, including pharmacokinetics and cellular trafficking, were discussed in detail in cancer types and infectious diseases. This review study opens a new and vital landscape to improve multidisciplinary therapeutics on mRNA-LNP through modulation of immunopharmacological responses in clinical trials. Keywords: Dendritic cell; Immune system; Immunogenicity; Lipid nanoparticles; Pharmacologic response; Toll-like receptor; mRNA delivery. Excipient for DNA/RNA Delivery Lipid For more product information, please contact us at: US Tel: 1-844-782-5734 US Tel: 1-844-QUAL-PEG CHN Tel: 400-918-9898 Email: sales@sinopeg.com

Review Adv Mater. 2023 Dec;35(51):e2303261. doi: 10.1002/adma.202303261. Epub 2023 Nov 1. Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy Abstract Messenger RNA (mRNA) has received great attention in the prevention and treatment of various diseases due to the success of coronavirus disease 2019 (COVID-19) mRNA vaccines (Comirnaty and Spikevax). To meet the therapeutic purpose, it is required that mRNA must enter the target cells and express sufficient proteins. Therefore, the development of effective delivery systems is necessary and crucial. Lipid nanoparticle (LNP) represents a remarkable vehicle that has indeed accelerated mRNA applications in humans, as several mRNA-based therapies have already been approved or are in clinical trials. In this review, the focus is on mRNA-LNP-mediated anticancer therapy. It summarizes the main development strategies of mRNA-LNP formulations, discusses representative therapeutic approaches in cancer, and points out current challenges and possible future directions of this research field. It is hoped that these delivered messages can help further improve the application of mRNA-LNP technology in cancer therapy. Keywords: cancer therapy; lipid nanoparticles; mRNA delivery; mRNA therapeutics. For more product information, please contact us at: US Tel: 1-844-782-5734 US Tel: 1-844-QUAL-PEG CHN Tel: 400-918-9898 Email: sales@sinopeg.com

We are excited to announce that XIAMEN SINOPEG BIOTECH CO., LTD. will be exhibiting at BIOCHINA 2025! Join us from March 12-15 in Suzhou to explore our latest innovations in Drug Delivery System (DDS). Let's connect, collaborate, and drive the future of biotech together! Booth: SD3-035 Date: March 12-15, 2025 Location: Suzhou International Expo Center Looking forward to meeting partners, clients, and industry leaders! Let’s innovate together. Follow BIOCHINA for more updates: BIOCHINA LinkedIn Homepage #BIOCHINA2025 #Biotech #LifeScienc

Int J Mol Sci. 2022 Oct 3;23(19):11707. doi: 10.3390/ijms231911707. PEG2-Induced Pyroptosis Regulates the Expression of HMGB1 and Promotes hEM15A Migration in Endometriosis Abstract Endometriosis (EMS) is a common gynecological disease. Prostaglandin E2 (PGE2), which induces chronic pelvic inflammation and cell pyroptosis, a form of programmed cell death based on inflammasome activation, are involved in EMS, but the extent of their involvement and roles remain unclear. The present study aimed to evaluate PGE2-induced pyroptosis in EMS and the influence of PGE2 in EMS progression. Using western blotting, it was found that the expressions of PGE2 and pyroptosis-related proteins (NLRP3, cleaved caspase-1, interleukin (IL)-1β and IL-18) were higher in EMS tissues than in normal endometrial tissues. The levels of PGE2, IL-1β, and IL-18 in the serum of patients with EMS and cell culture fluids were also detected. Using the transwell assay, we verified that PGE2 promoted hEM15A migration via the NLRP3/caspase-1 pyroptotic pathway, and PGE2-induced pyroptosis upregulated the expressions of high mobility group box 1 (HMGB1), E-cadherin, and vimentin. Immunohistochemistry analysis confirmed that PGE2-induced pyroptosis contributed to EMS invasion. These results suggest that PGE2-induced pyroptosis affects the progression of EMS by changing the migration ability of pyroptotic cells and upregulating the expression of HMGB1, E-cadherin, and vimentin. Our findings provide crucial evidence for new treatment pathways and use of anti-inflammatory drugs in EMS. Keywords: PGE2; cell migration; endometriosis; pyroptosis. For more product information, please contact us at: US Tel: 1-844-782-5734 US Tel: 1-844-QUAL-PEG CHN Tel: 400-918-9898 Email: sales@sinopeg.com

ACS Appl Bio Mater. 2021 Mar 15;4(3):2769-2780. doi: 10.1021/acsabm.1c00004. Epub 2021 Mar 2. Injectable and Degradable PEG Hydrogel with Antibacterial Performance for Promoting Wound Healing Abstract Injectable and degradable PEG hydrogel was prepared via Michael-type addition between cross-linking monomer 4-arm-PEG-MAL and two cross-linkers of hydrolysis degradable PEG-diester-dithiol and non-degradable PEG-dithiol, and it had a porous structure with the uniform pore size. The biocompatibility assays in vitro indicated that PEG hydrogel had excellent biocompatibility and can be degraded naturally without leading to any negative impact on cells. The results of antibacterial experiments showed that PEG hydrogel can inhibit the growth of bacteria. Furthermore, the Cell Counting Kit-8 (CCK-8) assay, LIVE/DEAD cell staining, and scratch healing experiments proved that PEG hydrogel can promote cell proliferation and migration, which had been further confirmed in in vivo experiments on the rat wound models. All experimental results demonstrated that PEG hydrogel is an injectable antibacterial dressing, which can promote the process of wound healing and has great potential in the field of wound healing. Keywords: PEG hydrogel; antibacterial; degradable; injectable; wound healing. For more product information, please contact us at: US Tel: 1-844-782-5734 US Tel: 1-844-QUAL-PEG CHN Tel: 400-918-9898 Email: sales@sinopeg.com